Tanaka I, et al. - As a part of this study, the efficacy and safety of ifosfamide (IFM) combination with recommended current supportive therapy were exploratively gauged for recurrent small-cell lung cancer (SCLC) in second-line and heavily treated setting. IFM monotherapy was not recommended for use in the case of refractory relapse or heavily treated SCLC. No additional exploration was necessitated among these population.